Early lymphopenia as a risk factor for chemotherapy-induced febrile neutropenia

American Journal of Hematology

Volumn 73, Issue 4, 2003, Pages 263-266

  Choi, Chul Won ^a   Sung, Hwa Jung ^a   Park, Kyong Hwa ^a   Yoon, So Young ^a   Kim, Seok Jin ^a   Oh, Sang Cheul ^a   Seo, Jae Hong ^a   Kim, Byung Soo ^a   Shin, Sang Won ^a   Kim, Yeul Hong ^a   Kim, Jun Suk ^a,b  

^a Korea University Ansan Hospital   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

Chemotherapy; Febrile neutropenia; Lymphopenia

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DACARBAZINE; DOCETAXEL; PACLITAXEL; STEROID;

ADOLESCENT; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG INDUCED DISEASE; FEBRILE NEUTROPENIA; FEMALE; HEPATOBILIARY SYSTEM CANCER; HUMAN; INCIDENCE; KOREA; LUNG NON SMALL CELL CANCER; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RISK FACTOR; SARCOMA; STOMACH CANCER;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; FEVER; HUMANS; INCIDENCE; LYMPHOCYTE COUNT; LYMPHOPENIA; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 0042309568     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.10363     Document Type: Article

References (12)

1. The International Antimicrobial Therapy Group of the European Organization for Research and Treatment of Cancer: Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. J Infect Dis 1978;137:14-29.
2. Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986;315:552-558.
3. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective two-center validation of a prediction rule. J Clin Oncol 1992;10:316-322.
4. Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of Antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-751.
5. Blay JY, Chauvin F, Cesne L, et al. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol 1996;14:636-643.
6. Watkins SM. Predicting neutropenia after chemotherapy for lymphoma. Leuk Lymphoma 1993;9:107-109.
7. Kitay-Cohen Y, Lishner M, Shelef A, Ravid M, Manor Y. Bone marrow involvement, in intensively treated patients with intermediate grade non-Hodgkin's lymphoma, is a risk factor for granulocytopenia and fever. Leuk Lymphoma 1996;20:333-336.
8. Voog E, Bienvenu J, Warzocha K, et al. Factors that predict chemotherapy-induced myelosuppression in lymphoma patients: role of the tumor necrosis factor ligand-receptor system. J Clin Oncol 2000;18:325-331.
9. Silber JH, Fridman M, DiPaola RS, Erder MH, Pauly MV, Fox KR. First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. J Clin Oncol 1998;16:2392-2400.
10. Metcalf D. Hematopoietic regulators: redundancy or subtlety? Blood 1993;82:3515-3523.
11. Porrata LF, Gertz MA, Inwards DJ, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 2001;98:579-585.
12. The American Society of Clinical Oncology. Updates of recommendations for the use of hematopoietic colony-stimulating factors: evidence based, clinical practice guidelines. J Clin Oncol 2000;18:3558-3585.